SUPERNUS PHARMACEUTICALS

Company snapshot

SUPERNUS PHARMACEUTICALS maintains 55 tracked programs across Epilepsy, Attention-Deficit/Hyperactivity Disorder (ADHD), Postpartum Depression, Focal Onset Seizures, Attention-Deficit/Hyperactivity Disorder, Sialorrhea, Spasticity, Epilepsies, Partial, Parkinson Disease, Attention Deficit Hyperactivity Disorder (ADHD), Impulsive Aggression Comorbid With ADHD, Parkinson's Disease. Momentum score: 2

• 1 approved product(s) across US/EU regulatory metadata.
• 55 active pipeline program(s) linked via ClinicalTrials.gov.
• 68 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for SUPERNUS PHARMACEUTICALS. Not investment advice.

• Peer + 0 momentum

  Xenon Pharmaceuticals

  TA overlap score 24.4

• Peer + 0 momentum

  H. Lundbeck A/S

  TA overlap score 23.4

• Peer + 0 momentum

  Addex Therapeutics

  TA overlap score 21.2

• Peer + 0 momentum

  Rapport Therapeutics

  TA overlap score 21

Recent activity

Latest pipeline, patent, and corporate events for SUPERNUS PHARMACEUTICALS.

1. Jun 8, 2026 Clinical update

   817P203 — Phase 2

2. Jun 8, 2026 Clinical update

   Topiramate IR — Phase 1

3. Jun 8, 2026 Clinical update

   Phase 2; Low Dose MYOBLOC — Phase 3

4. Jun 8, 2026 Clinical update

   Phase 2; Low Dose MYOBLOC (15,000 Units) — Phase 3

5. Jun 8, 2026 Clinical update

   MYOBLOC Low Dose — Phase 3

View all clinical trial activity →

• What is SUPERNUS PHARMACEUTICALS?

  SUPERNUS PHARMACEUTICALS is a pharma organization headquartered in Rockville, USA. It trades on NYSE under ticker SUPN. Primary therapeutic focus areas include Epilepsy, Attention-Deficit/Hyperactivity Disorder (ADHD), Postpartum Depression, Focal Onset Seizures, Attention-Defici

• Is SUPERNUS PHARMACEUTICALS publicly traded?

  Yes. SUPERNUS PHARMACEUTICALS is listed with ticker SUPN on NYSE per SEC EDGAR records linked on this profile.

• What drugs does SUPERNUS PHARMACEUTICALS develop or market?

  We link 25 drug profile(s) where SUPERNUS PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/supernus-pharmaceuticals-inc#company-drugs.

• What are the latest developments for SUPERNUS PHARMACEUTICALS?

  In the last 12 months our linked public records show 55 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does SUPERNUS PHARMACEUTICALS focus on?

  SUPERNUS PHARMACEUTICALS focuses on Epilepsy, Attention-Deficit/Hyperactivity Disorder (ADHD), Postpartum Depression based on our analysis of their pipeline programs and drug development activities.